Investigational Drug Information for Elesclomol
✉ Email this page to a colleague
What is the drug development status for Elesclomol?
Elesclomol is an investigational drug.
There have been 5 clinical trials for Elesclomol.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Carcinoma, Transitional Cell, Ovarian Neoplasms, and Neoplasms. The leading clinical trial sponsors are Synta Pharmaceuticals Corp., National Cancer Institute (NCI), and GOG Foundation.
Summary for Elesclomol
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 475 |
| WIPO Patent Applications | 235 |
| Japanese Patent Applications | 21 |
| Clinical Trial Progress | Phase 2 (2007-08-01) |
| Vendors | 53 |
Recent Clinical Trials for Elesclomol
| Title | Sponsor | Phase |
|---|---|---|
| Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Synta Pharmaceuticals Corp. | Phase 1 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | National Cancer Institute (NCI) | Phase 2 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | GOG Foundation | Phase 2 |
Clinical Trial Summary for Elesclomol
Top disease conditions for Elesclomol
Top clinical trial sponsors for Elesclomol
US Patents for Elesclomol
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
